| 000 | 01741 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250517230634.0 | ||
| 264 | 0 | _c20181211 | |
| 008 | 201812s 0 0 eng d | ||
| 022 | _a1177-8881 | ||
| 024 | 7 |
_a10.2147/DDDT.S166402 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDuan, Wendu | |
| 245 | 0 | 0 |
_aTargeted and synergistic therapy for hepatocellular carcinoma: monosaccharide modified lipid nanoparticles for the co-delivery of doxorubicin and sorafenib. _h[electronic resource] |
| 260 |
_bDrug design, development and therapy _c2018 |
||
| 300 |
_a2149-2161 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aCarcinoma, Hepatocellular _xdrug therapy |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 |
_aCell Proliferation _xdrug effects |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 |
_aDoxorubicin _xadministration & dosage |
| 650 | 0 | 4 |
_aDrug Carriers _xchemistry |
| 650 | 0 | 4 | _aDrug Delivery Systems |
| 650 | 0 | 4 | _aDrug Screening Assays, Antitumor |
| 650 | 0 | 4 | _aHep G2 Cells |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLipids _xchemistry |
| 650 | 0 | 4 |
_aLiver Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aLiver Neoplasms, Experimental _xdrug therapy |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 | _aMice, Inbred BALB C |
| 650 | 0 | 4 | _aMice, Nude |
| 650 | 0 | 4 |
_aMonosaccharides _xchemistry |
| 650 | 0 | 4 |
_aNanoparticles _xchemistry |
| 650 | 0 | 4 |
_aSorafenib _xadministration & dosage |
| 650 | 0 | 4 | _aStructure-Activity Relationship |
| 700 | 1 | _aLiu, Yan | |
| 773 | 0 |
_tDrug design, development and therapy _gvol. 12 _gp. 2149-2161 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2147/DDDT.S166402 _zAvailable from publisher's website |
| 999 |
_c28657956 _d28657956 |
||